

FORM 3**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HENDERSON ERIC</u> (Last) (First) (Middle) <u>BIOFORCE NANOSCIENCES HOLDINGS, INC.</u> <u>1615 GOLDEN ASPEN DRIVE, SUITE 101</u> (Street) <u>AMES IA 50010</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/24/2006</u>	3. Issuer Name and Ticker or Trading Symbol <u>BIOFORCE NANOSCIENCES HOLDINGS, INC. [BFNH]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer Other <input checked="" type="checkbox"/> (give title below) (specify below) <u>CEO & President</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) <u>03/10/2006</u>
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>3,669,920⁽¹⁾</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Option (Right to buy)</u>	<u>02/24/2006⁽²⁾</u>	<u>12/20/2010</u>	<u>Common stock</u>	<u>356,310</u>	<u>1.26⁽³⁾</u>	<u>D</u>	
<u>Option (Right to buy)</u>	<u>02/24/2006⁽⁴⁾</u>	<u>10/25/2011</u>	<u>Common stock</u>	<u>5,345</u>	<u>0.34⁽⁵⁾</u>	<u>I</u>	<u>By member of household⁽⁶⁾</u>

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (Right to buy)	02/24/2006 (4)	04/01/2013	Common Stock	41,570	0.84 ⁽⁷⁾	I	By member of household (6)
Option (Right to buy)	02/24/2006 (4)	12/20/2015	Common Stock	5,939	1.26 ⁽³⁾	I	By member of household (6)

Explanation of Responses:

1. Previously incorrectly reported as 3,670,155 due to a mathematical error.
2. The option vested and became exercisable as to 118,770 shares on February 24, 2006, and 118,770 shares on December 20, 2006, and will vest and become exercisable as to 118,770 shares on December 20, 2007. The vesting increments were previously reported as 118,758 shares due to a mathematical error.
3. The exercise price was previously incorrectly reported as \$1.50 per share.
4. The option is fully vested and exercisable.
5. The exercise price was previously incorrectly reported as \$0.40 per share.
6. Dr. Henderson shares a household with Asrun Kristmundsdottir, the Director of Business Management for the issuer's wholly-owned subsidiary BioForce Nanosciences, Inc. Dr. Henderson disclaims beneficial ownership of all options held by Ms. Kristmundsdottir.
7. The exercise price was previously incorrectly reported as \$1.00 per share.

Remarks:

By: Laura E. Carabillo,
Attorney in Fact for 06/15/2007
Eric R. Henderson

** Signature of Reporting Date
Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.